May 21, 2023Open Access

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

Key Points

Key points are not available for this paper at this time.

Abstract

Among patients with COPD who had type 2 inflammation as indicated by elevated blood eosinophil counts, those who received dupilumab had fewer exacerbations, better lung function and quality of life, and less severe respiratory symptoms than those who received placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; BOREAS ClinicalTrials.gov number, NCT03930732.).

KI fragen

Bookmark

View Full Paper

Cite This Study

Bhatt et al. (Sun,) studied this question.

synapsesocial.com/papers/69dd4ad9656f15f1fc100fd7 https://doi.org/https://doi.org/10.1056/nejmoa2303951

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Serum cytokine profiling and enrichment analysis reveal the involvement of immunological and inflammatory pathways in stable patients with chronic obstructive pulmonary disease2014 · 33 citations
2Interleukin‐13: prospects for new treatments2009 · 87 citations
3Impact of mild exacerbation on COPD symptoms in a Japanese cohort2016 · 6 citations
4Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease1998 · 2,328 citations
5Burden of disease associated with a COPD eosinophilic phenotype2018 · 22 citations

KI fragen

Bookmark

View Full Paper